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a b s t r a c t
Renal denervation is a new intervention to treat resistant hypertension. By applying radio-
frequency (RF) to renal arteries, sympathetic nerves in adventitia layer of vascular wall can
be denervated. Sympathetic hyperactivity is an important contributory factor in hyperten-
sion of hemodialysis patients. Hyperactive sympathetic nervous system aggravates hyper-
tension and it can cause complications like left ventricular hypertrophy, heart failure,
arrhythmias and atherogenesis. Our report illustrates the use of renal denervation using
conventional RF catheter for uncontrolled hypertension in a patient with Alport syndrome
and rejected renal allograft. Progressive and sustained reduction of blood pressure was
obtained post-procedure and at 24 months follow-up with antihypertensives decreased
from 6 to 2 per day, thereby demonstrating the safety, feasibility, and efﬁcacy of the
procedure. There are some reports available on the usefulness of this technique in hemodi-
alysis patients; however, there are no studies of renal denervation in patients with Alport
syndrome and failed allograft situation.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Renal denervation is a novel therapy for resistant hyperten-
sion. Here, we present an interesting case with progressive and
sustained reduction of systemic blood pressure (BP) following
renal sympathetic nerve denervation (SND) using convention-
al radiofrequency (RF) catheter for resistant hypertension in a
failed renal allograft recipient with Alport syndrome on
maintenance hemodialysis.* Corresponding author.
E-mail address: narayanarajucardio@gmail.com (N. Raju).
http://dx.doi.org/10.1016/j.ihj.2015.12.004
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier2. Case presentation
A 19-year-old male presented with history of continuous
occipital headache of one-year duration. He was diagnosed to
have chronic kidney disease (CKD) stage-V due to Alport's
syndrome at 12 years of age and received a renal allograft from
his mother after a year of ambulatory peritoneal dialysis.
Allograft failure occurred due to chronic rejection a year post-
transplant and maintenance hemodialysis was initiated. B.V. All rights reserved.
Fig. 1 – Renal angiogram showing right renal artery.
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Treatment compliance was maintained with strict family
supervision. Dietary salt and ﬂuid restriction was kept in
check. Ultraﬁltration was done on hemodialysis to maintain
the post-dialysis ideal weight with regular reassessments.
Despite the above, the BP was resistant to pharmacological
treatment with six different anti-hypertensive drugs.
On examination, he had pulse rate of 60/min, BP of
244/132 mmHg, respiratory rate 16/min, and the temperature
was 98.6 8F. Cardiovascular system examination was normal
and chest was clear. His hemoglobin was 10.5 mg/dL and
creatinine 3.4 mg/dL. The 24 h mean ambulatory BP was
223/125 mmHg. Renal angiogram revealed a good sized right
renal artery (Fig. 1) and a small left renal artery with no
evidence of renal artery stenosis. In view of him being
diagnosed to have resistant hypertension, renal SND was
planned. After discussing risks and beneﬁts of renal artery
denervation, a 5F (St. Jude Medical, CA, USA) conventional RF
ablation catheter (Fig. 2) was advanced into the right renal
artery through Mullins sheath. A Stockert RF generator was
used to deliver RF energy in unipolar mode. We delivered RF
energy for 45–60 s each of 10 W and created 5 focal lesions,Fig. 2 – Ablation catheter in right renal artery.longitudinally separated along the length of right renal artery.
Left renal artery was not suitable for RF ablation due to its
smaller diameter. The cutoff point was taken as a reduction in
impedance by 10%. The catheter tip impedance was monitored
continuously. RF delivery was stopped if there was rise in
impedance by more than 5 V. BP was 172/103 mmHg following
the procedure. Post-procedure renal angiogram was done to
assess for procedural complications within the renal arteries.
Next day BP was 141/92 mmHg with same medications. The
patient was discharged on second post-procedure day. A
complete physical examination including ofﬁce BP monitor-
ing, drug compliance and renal proﬁle, which were assessed at
baseline were repeated at 1, 3, 6, 12, 18, 24 months post-SND.
He was on home BP monitoring. During 24-month follow-up,
his BP continued to fall and his antihypertensives were
reduced. 24 h mean ambulatory BP 24 months post-procedure
was 132/84 mmHg (i.e. 91/41 mmHg reduction) while on two
antihypertensives.
3. Discussion
Drug-resistant hypertension is very common in patients with
CKD Stage V treated by hemodialysis. The prevalence of
hypertension has been evaluated to be over 50% and upto
80%.1,2 The mortality ﬁgures remain high in these patients due
to cardiovascular complications of CKD and hypertension.
Hemodialysis patients show sympathetic hyperactivity.3
Sympathetic nervous system (SNS) is vital in the initiation
and maintenance of high BP.4 The degree of SNS activation
correlates with the severity of hypertension.5 The renal
sympathetic nerves arise from T10-L1 and enter the kidneys
through the adventitia of the renal arteries. Catheter-based
SND of the renal sympathetic nerves in these patients causes
reduction of renal sympathetic afferent and efferent activity
and the BP can be lowered. SND is a minimally invasive
procedure involving the application of RF energy in short
bursts along the length of the main renal arteries to ablate the
renal nerves that lie within and just beyond the adventitia of
the renal artery as they pass to the kidneys.
The feasibility, safety, and efﬁcacy of the procedure have
already been demonstrated in the Symplicity-1 trial. 153
patients with drug-resistant hypertension underwent bilateral
application of RF to the renal arteries.6A signiﬁcant BP reduction
at 1-month follow-up of 14 and 10 mmHg (systolic and diastolic,
respectively) was followed by a sustained response with a
pronounced systolic and diastolic BP reduction of 32 and
14 mmHg, respectively, at 36 months. Symplicity HTN-2
randomized trial conﬁrmed the above ﬁndings. In this study,
106 patients with resistant hypertension were randomized to
catheter-based therapy in addition to conventional antihyper-
tensive medications, versus antihypertensive medications
only, in a 1-to-1 fashion.5 There was a signiﬁcant difference
in BP changes from baseline between patients treated with
catheter-based renal sympathectomy and those treated medi-
cally, with a mean BP difference of 33/14 mmHg between the
groups at 36 months. In Symplicity 1 and Symplicity 2 trials,
simplicity catheters were used, which are for single use only and
expensive for developing countries. In our case, we used
conventional RF catheter, which is reusable and the cost of
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in our case where he has undergone renal transplant and on
maintenance hemodialysis, which is expensive.
The safety, feasibility, and efﬁcacy of the SND procedure
have also been demonstrated in hemodialysis patients.7–9
Narasimhan and co-workers8 have reported a mean BP
reduction of 43.5/21 mmHg among 8 patients including those
with CKD on maintenance hemodialysis. Yaduvanshi et al.9
have demonstrated a mean BP reduction of 41.8/20.4 mmHg
among 9 patients with end stage renal disease. Till date, there
are no published reports of renal denervation in patients with
Alport syndrome and prior renal transplantation. Our case
demonstrated acute response to renal denervation, which
persisted after 24 months, despite the presence of failed renal
allograft in situ.
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